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Abstract
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer
patients in the UK. There has been significant debate in the management of oropharyngeal cancer in the last
decade, especially in light of the increased incidence, clarity on the role of the human papilloma virus in this
disease and the treatment responsiveness of the human papilloma virus positive cancers. This paper discusses
the evidence base pertaining to the management of oropharyngeal cancer and provides recommendations on
management for this group of patients receiving cancer care.
Recommendations
• Cross-sectional imaging is required in all cases to complete assessment and staging. (R)
• Magnetic resonance imaging is recommended for primary site and computed tomography scan for neck and
chest. (R)
• Positron emission tomography combined with computed tomography scanning is recommended for the
assessment of response after chemoradiotherapy, and has a role in assessing recurrence. (R)
• Examination under anaesthetic is strongly recommended, but not mandatory. (R)
• Histological diagnosis is mandatory in most cases, especially for patients receiving treatment with curative
intent. (R)
• Oropharyngeal carcinoma histopathology reports should be prepared according to The Royal College of
Pathologists Guidelines. (G)
• Human papilloma virus (HPV) testing should be carried out for all oropharyngeal squamous cell carcinomas as
recommended in The Royal College of Pathologists Guidelines. (R)
•Human papilloma virus testing for oropharyngeal cancer should be performed within a diagnostic service where
the laboratory procedures and reporting standards are quality assured. (G)
• Treatment options for T1–T2 N0 oropharyngeal squamous cell carcinoma include radical radiotherapy or
transoral surgery and neck dissection (with post-operative (chemo)radiotherapy if there are adverse
pathological features on histological examination). (R)
• Transoral surgery is preferable to open techniques and is associated with good functional outcomes in
retrospective series. (R)
• If treated surgically, neck dissection should include levels II–IV and possibly level I. Level IIb can be omitted if
there is no disease in level IIa. (R)
• If treated with radiotherapy, levels II–IV should be included, and possibly level Ib in selected cases. (R)
• Altering the modalities of treatment according to HPV status is currently controversial and should be
undertaken only in clinical trials. (R)
• Where possible, patients should be offered the opportunity to enrol in clinical trials in the field. (G)
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Introduction and epidemiology
The incidence of oropharyngeal squamous cell carcin-
oma (OPSCC) is increasing significantly in developed
countries.1 In the USA, the incidence increased by 22
per cent from 1.53 per 100 000 to 1.87 per 100 000
between 1999 and 2006, after showing no change
between 1975 and 1999. The UK has seen a doubling
of incidence between 1990 and 2006. There has been a
further doubling in incidence between 2006 and 2010.
The increasing incidence of OPSCC is due to human
papilloma virus (HPV) infection, with HPV-16 being
the predominant subtype responsible. The proportion
of cases with evidence of HPV infection has risen
rapidly and HPV is now responsible for over 70 per
cent of OPSCCs in Europe and the USA.1,2 The rise
in HPV-related OPSCC has been called an ‘epidemic’
and is expected to continue.
Clinical presentation
Patients often present with a painless neck lump, with
few other symptoms. They may also complain of a
sore throat or tongue, otalgia, pain and/or difficulty
swallowing and/or a change in voice quality (hot
potato voice).
Assessment and staging
Clinical examination
Flexible direct endoscopy of the upper aerodigestive
tract is now available in virtually all ear, nose and
throat clinics in the UK. It is vital for assessing the
limits of spread, such as direct through and through
invasion of the soft palate from anterior to posterior
surfaces, the inferior extent of lateral pharyngeal wall
tumours into the vallecula and pyriform fossa, and
the superior extension of tonsillar cancers into the post-
nasal space and skull base.
Imaging considerations
Cross-sectional imaging is required in all cases to com-
plete assessment and staging. Magnetic resonance
imaging (MRI) scanning with contrast is optimal for
staging the primary tumour, particularly when asses-
sing soft tissue spread, such as in the tongue base
and/or body of the tongue.3,4 Computed tomography
(CT) scanning may also be required, particularly to
assess the extent of nodal disease and bony invasion,
e.g. body of the mandible and skull base in tonsillar
tumours and cervical spine in posterior pharyngeal
wall tumours.
The presence of nodal metastases should be evalu-
ated by CT or MRI in all patients. Ultrasound with or
without needle biopsy should be carried out for all
patients presenting with a neck lump and is an accur-
ate method of staging nodal disease in experienced
hands.
Distant metastases should be assessed by CT scan-
ning of the chest and upper abdomen, to exclude meta-
static disease to the lungs and liver.3 Magnetic
resonance imaging scanning is not suitable for this
due to the relatively slow acquisition process leading
to movement artefact caused by breathing.
Fluoro-deoxy-glucose positron emission tomog-
raphy combined with computed tomography (F-FDG
PET–CT) scanning may be used to give additional
staging information when it is available, particularly
where staging is difficult clinically (e.g. patient with
trismus) or where there is uncertainty on other
imaging and/or equivocal findings that would preclude
radical treatment. Positron emission tomography (PET)
also has a role in the assessment of recurrent tumours
and can detect recurrence at primary sites, neck nodes
and/or distant metastases.
Supported by the results of the UK PET-Neck rando-
mised controlled trial (RCT) study,5 F-FDG PET–CT
scanning is now also recommended for the assessment
of response approximately three months post-chemora-
diotherapy, particularly in patients with advanced
nodal disease. PET-CT guided active surveillance
showed similar survival outcomes to the planned
neck dissection arm, but resulted in considerably
fewer neck dissections, and fewer complications, and
was cost effective, supporting its use in routine
practice.5
Examination under anaesthetic and panendoscopy
Examination under anaesthetic and panendoscopy is
strongly recommended to assess the extent and resect-
ability of the primary tumour and to exclude second
primaries, especially in hypopharynx and oesopha-
gus. Examination under anaesthetic is mandatory if
thorough endoscopic examination is not possible in
the clinic as above and/or if no biopsy can be
obtained.
Recommendations
• Cross-sectional imaging is required in all
cases to complete assessment and staging (R)
• Magnetic resonance imaging is recommended
for primary site and CT scan for neck and
chest (R)
• Positron emission tomography combined with
computed tomography scanning is
recommended for the assessment of response
after chemoradiotherapy, and has a role in
assessing recurrence (R)
• Examination under anaesthetic is strongly
recommended, but not mandatory (R)
Pre-treatment staging
Pre-treatment staging for the primary tumour based
on the tumour–node–metastasis classification (7th
edition) for oropharyngeal tumours is shown in Box I.
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BOX I
TNM STAGING FOR OROPHARYNGEAL SQUAMOUS
CELL CARCINOMA
• TX: Primary tumour cannot be assessed
• T0: No evidence of primary tumour
• Tis: Carcinoma in situ
• T1: Tumour 2 cm or less in greatest dimension
• T2: Tumour larger than 2 cm but 4 cm or less in
greatest dimension
• T3: Tumour larger than 4 cm in greatest
dimension or extension to lingual surface of
epiglottis
• T4a: Tumour invades the larynx, deep/extrinsic
muscle of tongue, medial pterygoid, hard palate
or mandible
• T4b: Tumour invades lateral pterygoid muscle,
pterygoid plates, lateral nasopharynx, or skull
base or encases carotid artery
Pathology
Formal tissue biopsy of the primary cancer is one of the
cornerstones of the management pathway in oropharyn-
geal cancer. Tumours can be biopsied under local or no
anaesthetic in the clinic. Otherwise, direct biopsy and
staging under general anaesthetic is necessary.
In very few circumstances, a positive cancer diagno-
sis from fine needle aspiration (FNA) of involved
nodes may suffice, provided the cytology result has
been considered in conjunction with the clinical pres-
entation and appropriate imaging at a head and neck
cancer multidisciplinary team meeting. Such circum-
stances may arise in a person who is unfit to have an
anaesthetic for an open biopsy and in whom local
anaesthetic biopsies have not been successful. There
is limited information on the reliability of p16 and
HPV tests on FNA material and HPV testing is not cur-
rently routinely recommended on FNA samples.
The majority of oropharyngeal cancers are squamous
cell carcinomas. It is recommended that they are
reported according to The Royal College of
Pathologists UK Guidelines for the histopathology
reporting of mucosal malignancies of the pharynx
(2013). Human papilloma virus testing is a core item
for OPSCC to allow the stratification of treatment out-
comes. Human papilloma virus status should be
assessed using validated methods with appropriate con-
trols. Human papilloma virus testing for oropharyngeal
cancer should be performed within a diagnostic service
where the laboratory procedures and reporting standards
are quality assured. The immunohistochemical identifi-
cation of over-expression of p16 protein is a useful
screeningmethod for HPV infection as HPV-associated
carcinomas show strong nuclear and cytoplasmic
expression of p16 in over 70 per cent malignant cells
and p16-negative cases are almost certainly not HPV
associated. Carcinomas showing p16 over-expression
should have the presence of HPV confirmed by high-
risk HPV DNA in situ hybridisation, if possible.
Polymerase chain reaction analysis for HPV is not cur-
rently recommended in clinical practice as there is a
risk of false positive results from formalin-fixed
tissues.6
Recommendations
• Histological diagnosis is mandatory in most
cases, especially for patients receiving
treatment with curative intent (R)
• Oropharyngeal carcinoma histopathology
reports should be prepared according to The
Royal College of Pathologists Guidelines (G)
• Human papilloma virus testing should be
carried out for all oropharyngeal squamous
cell carcinomas as recommended in The Royal
College of Pathologists Guidelines (R)
• Human papilloma virus testing for
oropharyngeal cancer should be performed
within a diagnostic service where the
laboratory procedures and reporting
standards are quality assured (G)
Prognosis
Prognosis is dependent on stage at presentation as well
as HPV status.7 The status of human papilloma virus is
a strong and independent prognostic factor for survival,
and HPV-positive OPSCC has a 58 per cent reduction
in the risk of death compared with HPV-negative
OPSCC (hazard ratio 0.42, 95 per cent; confidence
interval 0.27–0.66), with 3 year overall survival rates
of 82.4 per cent for HPV-positive disease compared
with 57.1 per cent (p< 0.001) for HPV-negative
disease.8 Factors including smoking, particularly
current smoking,9,10 which may be a surrogate of
genetic instability, and nodal stage, may influence prog-
nosis in HPV-positive OPSCC. Several immunological
markers have also been shown to correlate with progno-
sis and a UK study showed significant associations
between the presence of tumour infiltrating lympho-
cytes and improved survival.11 Although there are no
head-to-head comparisons of primary surgical vs non-
surgical management for OPSCC, similar survival
outcomes have been reported in studies of primary che-
moradiotherapy and of surgery followed by post-
operative radiotherapy (RT) and/or chemoradiotherapy,
albeit there is a lack of prospective randomised trials of
surgical management.8,12–14
To date, there is no evidence that patients with HPV-
positive and HPV-negative OPSCC should be treated
differently, outside of the context of randomised,
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controlled clinical trials. In view of the excellent prog-
nosis from lower-risk HPV-positive disease, current
and future UK studies (De-Escalate HPV,
ISRCTN33522080 and PATHOS, UKCRN ID 18645)
will investigate whether reduced intensity treatment
can maintain favourable outcomes but reduce acute
and late toxicity for patients. On the other hand,
because HPV-negative and higher risk HPV-positive
patients have a poorer prognosis, future trials
(CompARE, ISRCTN41478539) will investigate
whether escalating treatment will result in better outcomes
for these patients.
Management
Early (T1–T2 N0) oropharyngeal carcinoma
General principles of management. Early stage (T1–T2
N0 M0) oropharyngeal carcinoma should ideally be
treated with single modality therapy, either primary
surgery or RT. There are no high-quality comparative
studies of the two treatment modalities within the same
population. Retrospective case series demonstrate five-
year disease-specific survival rates of 81–100 per cent
for primary surgery15(with adjuvant therapy where appro-
priate) and 77–89 per cent for primary RT, with surgical
salvage.16 Treatment decisions are made based on the size
and position of the tumour overall functional deficit.
Surgical management of early (T1–T2 N0) oropharyn-
geal cancer. Surgery for T1–T2 N0 OPSCC should
usually be carried out transorally, either by transoral
laser microsurgery (TLM) or transoral robotic surgery
(TORS). Oncologic results after transoral resection of
the oropharynx appear to be comparable to open
surgery and good functional outcomes have been
reported after transoral surgery in retrospective
series.17 Open approaches are associated with increased
severe morbidity and treatment complications and have
now fallen out of favour for early stage disease.
During TLM, tumours are removed in several (at
least two) planned pieces following trans-tumoural
resection. This can cause difficulty in pathological
scrutiny of the resected tissue to determine margins,
which is compounded by laser artefact and difficulty
in orientation. Representative marginal biopsies, taken
from the peripheral mucosal resection margins and
tumour bed can be carried out and examined patho-
logically to help rule out the presence of residual
microscopic disease after TLM. In contrast to TLM,
TORS involves en bloc removal of the tumour in the
majority of cases. As a result, surgical margins can
be more easily interpreted.
About 10–31 per cent of patients who are clinically
T1–T2 N0 will have occult nodal disease. Therefore,
patients having surgery to the primary should also
undergo ipsilateral selective neck dissection. Surgery
to the contralateral neck may also be considered in
tumours arising at or very near the midline (in the
soft palate, tongue base or posterior pharyngeal wall)
in order to obtain pathological staging of the contralat-
eral neck. Evidence suggests dissecting levels II, III
and IV and possibly level I if there is anterior exten-
sion.18 Retrospective studies suggest that level IIb
does not need to be dissected, as long as there are no
findings pre-operatively of level IIa disease. For trans-
oral resections, the neck dissection may be performed
at the same time, or as a staged procedure, around
two weeks before transoral resection of the primary.
A staged approach may help prevent the development
of a fistula if there is lateral pharyngeal wall transoral
resection. Concomitant transoral resection and neck
dissection can also be carried out and good results
have been reported. In the latter, local muscle transpos-
ition (digastric or sternomastoid) can be performed to
augment any defect and decrease risk of fistula. For
any transoral resection of the oropharynx, ligation of
the individual feeding vessels from the external
carotid artery should be performed (ascending pharyn-
geal, lingual and facial branches) to limit the risk of
potentially life-threatening haemorrhage. This should
be done in any neck dissection performed as a prior
staged procedure.
Although the goal for T1–T2 N0 disease should be
single modality treatment, adjuvant RT and/or chem-
oradiotherapy may be required due to adverse patho-
logical features for recurrence following surgery.
Post-operative RT should be planned using the same
principles as radical RT; a dose of 60 Gy in 30 fractions
is typically recommended. Adjuvant treatment may
affect functional outcomes following surgery.
Radical RT for early oropharyngeal cancer. Prior to RT,
patients should undergo dietetic, speech and language
therapy and dental review. A total dose equivalent of
70 Gy in 35 fractions is used in radical treatment.
Hypofractionated schedules (typically 65–66 Gy in 30
fractions) are frequently used. Patients are managed as
category 1 patients and RT should be completed on time.
Target volume definition is performed using a con-
trast-enhanced planning CT scan. Co-registration of
the planning CT scan with the diagnostic MRI scan
can aid target volume delineation. An anatomical
(inclusion of the whole oropharynx) or geometric
(inclusion of gross tumour volume with a defined
margin) approach may be used for primary target
volume delineation. Prophylactic RT should be given
to the ipsilateral cervical lymph nodes for lateralised
(e.g. tonsillar) tumours and to both sides of the neck
for non-lateralised tumours (defined as tumours
which involve greater than 1 cm of a midline structure
e.g. soft palate and/or tongue base). Radiotherapy to
levels II, III and IVa is recommended; level Ib may
also be included in cases with anterior extension of
tumour and/or involvement of the anterior tonsillar
pillar. Planning can be carried out using three-dimen-
sional conformal planning (typically using a ‘wedged
pair’ of RT fields) or intensity modulated radiotherapy
(IMRT) and/or Arc therapy.
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Recommendations
• Treatment options for T1–T2 N0
oropharyngeal squamous cell cancer include:
radical radiotherapy or transoral surgery and
neck dissection (with post-operative
(chemo)radiotherapy if there are adverse
pathological features on histological
examination) (R)
• Transoral surgery is preferable to open
techniques and is associated with good
functional outcomes in retrospective series (R)
• If treated surgically, neck dissection should
include levels II–IV and possibly level I. Level
IIb can be omitted if there is no disease in level
IIa (R)
• If treated with RT, levels II–IV should be
included, and possibly level Ib in selected
cases (R)
Advanced (T3–T4 N0 and T1–T4 N1–N3)
oropharyngeal cancer
General principles of management. A thorough review
of the literature relating to the management of oropha-
ryngeal cancer was published as a Cochrane report in
2009. The only evidence of statistically significant
benefit was for the addition of concomitant chemother-
apy to post-operative RT.19 All other treatment compar-
isons did not show any statistical differences.
In recent years, there has been a tendency to offer
primary RT and/or chemoradiotherapy for oropharyn-
geal carcinoma, as part of an ‘organ preservation’
strategy. Although there are no good head-to-head com-
parisons of primary surgery and chemoradiotherapy for
stage III/IV OPSCC, outcomes from randomised trials
of chemoradiotherapy (e.g. RTOG 0129) are at least
comparable to the results of surgical series. One poten-
tial concern with an organ preservation approach is
that although salvage surgery has been shown to have
a high success rate for laryngeal cancer, the success
rate of salvage surgery is not the same in other head
and neck sites, such as the oropharynx.
The 2013 National Head and Neck Cancer Audit (9th
DAHNO Report) concluded that variation in treatment
strategies for OPSCC is evident across cancer networks
in England and Wales. This is not surprising in view of
the fact that current published evidence does not provide
a consensus view to define the most appropriate treat-
ment strategy. Treatment decisions for individual
patients will depend on the size, position and overall
functional deficit, as well as on patient preference and
local expertise. Human papilloma virus status has a pro-
found influence on prognosis, and in future, could
potentially affect selection of treatment modality.
Recruitment into randomised controlled clinical trials
addressing these issues is highly recommended.
Surgical management of advanced oropharyngeal car-
cinoma. Where facilities and expertise exist, transoral
resection (by TLM or TORS) of base of tongue, tonsil
and pharyngeal wall primary tumours (usually with
post-operative (chemo)radiotherapy) has been shown
to offer rates of cure which appear to be as good as
primary chemoradiotherapy in non-randomised compar-
isons, with promising functional results. Transoral resec-
tion is generally restricted to T1–T2 tumours, although
resection of some T3 tumours may be considered if it
is anticipated that negative margins can be achieved
via a transoral approach. Transoral resection is rarely
appropriate for T4 primary tumours. Also, where a
larger resection of the soft palate is required, the
general consensus is that surgery gives a poor functional
outcome. It should be noted that approximately 80 per
cent of patients who undergo primary surgery will
also receive post-operative RT or chemoradiotherapy.
If transoral resection is not appropriate, e.g. for large
primary tumours, then chemoradiotherapy should be
considered. Alternatively, open surgical procedures
may be considered, which usually require paramedian
mandibulotomy for access and reconstruction with a
flap. Trans-cervical pharyngotomy alone can be used
for tongue base resections. Other approaches, such as
glossotomy and lingual release can be used but are not
often employed. Reconstruction is generally performed
using radial artery free flaps or anterolateral thigh free
flaps. Reconstruction using pedicled flaps, such as pec-
toralis major should be considered sub-optimal.
Functional results following open surgery can be poor,
particularly when followed by adjuvant therapy.
There are several published case series that report the
likelihood of nodal metastasis for advanced oropharyn-
geal carcinoma to be over 50 per cent. When managing
T3 and T4 oropharyngeal cancers, the N0 neck should
be treated electively. When managing the N0 neck sur-
gically, a selective level II, III and IV neck dissection is
generally recommended, and in some cases level I may
be included. All patients with node positive disease
should have a modified neck dissection or at least
level I–IV selective neck dissection.
Primary chemoradiotherapy for loco-regionally advanced
(stage III–IVb) oropharyngeal carcinoma. Chemoradio-
therapy (organ preservation) is an effective treatment
choice for advanced head and neck tumours. A RT
dose equivalent of 70 Gy in 2 Gy fractions with con-
current cisplatin chemotherapy is considered standard
for stage III and/or IV OPSCC. Concurrent weekly
cetuximab (a monoclocal antibody targeting the epider-
mal growth factor receptor) may be given with RT if
there is a contraindication to platinum chemotherapy
(e.g. renal dysfunction or hearing impairment).
Alternatively, radical RT alone can be given for patients
with advanced disease who are not fit for concurrent
treatment, particularly if they are over 70 years of age
when the benefits of concurrent chemotherapy are
reduced. Induction chemotherapy may be considered
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for patients with advanced (T4, N3, N2c) disease to
reduce the risk of distant metastases20 and for selected
other patients with bulky primary (T4) and/or nodal
disease (N3), but there is currently no high-quality evi-
dence of its efficacy in these indications.
The principles of RT outlining and planning are as
described for earlier stage disease. Neck nodes should
be included in the treatment fields depending on their
probability of involvement and according to the
DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI,
RTOG, TROG consensus guidelines and atlas which
were updated in 2013.21 Radiotherapy to levels Ib–IVa,
V(a,b) and the retropharyngeal nodes (level VIIa) at the
level of the oropharynx is generally recommended in a
node positive neck. The retrostyloid space (level VIIb)
is included when level II is involved and the supraclavicu-
lar fossa (levels IVb and Vc) is included when level IVa
or V is involved. Radiotherapy should be given to at least
the ipsilateral cervical lymph nodes for lateralised
tumours and to both sides of the neck for non-lateralised
tumours. The issue of whether the contralateral neck
should be treated in patients with lateralised oropharyn-
geal tumours and advanced (N2+) nodal disease
remains controversial and will depend on local practice.
Chemoradiotherapy is associated with greater toxicity
than RT alone and late toxicity, particularly swallowing
dysfunction, can have a significant impact on quality of
life.22 Gastrostomy tube dependence rates of up to 24 per
cent at 1 year and 14 per cent at 2 years post-chemora-
diotherapy have been reported, although others have
reported much lower rates. Improvements in RT techni-
ques (including IMRT) have been shown to reduce late
complications following RT. The UK PARSPORT ran-
domised study showed a significant reduction in xeros-
tomia rates with parotid sparing IMRT compared with
conventional RT (using parallel opposed fields) in
patients with advanced OPSCC.23 Ongoing studies are
exploring the role of IMRT in improving swallowing
function following RT, by reducing radiation dose deliv-
ery to the pharyngeal constrictor muscles and other
swallowing structures.
Traditionally, patients with advanced nodal disease
(N2 or N3) being treated by chemoradiotherapy
required a planned neck dissection, with little evidence
to support whether neck dissection before or after che-
moradiotherapy is more effective. There is now level I
evidence from the PET-Neck trial that a PET–CT
guided active surveillance policy, with neck dissection
only being carried out if residual abnormal or equivocal
nodes are present on imaging 10–12 weeks after the
end of chemoradiotherapy, results in similar survival
rates to a planned neck dissection, with less morbidity,
and with higher cost effectiveness.5
Post-operative radiotherapy and chemoradiotherapy for
advanced oropharyngeal carcinoma. The indications
for post-operative RT and chemoradiotherapy for
OPSCC depend on pathological risk factors for recur-
rence common to most head and neck squamous
carcinomas. Randomised controlled trials and a meta-
analysis of results confirm that patients with extra-cap-
sular invasion and/or microscopically involved
(<1 mm) surgical resection margins around the
primary tumour experience significant benefit in
terms of overall and disease free survival from post-
operative chemoradiotherapy compared with RT
alone.24 Post-operative chemoradiotherapy is asso-
ciated with significant acute and late toxicity and is
not generally recommended in patients over 70 years
of age and/or patients with poor performance status.
Indications for post-operative RT alone include mul-
tiple nodal metastasis, T3 or T4 tumours, and
tumours with other adverse features, including peri-
neural or lymphovascular invasion. Patients with
close (1–5 mm) surgical margins around the primary
tumour may be treated with post-operative chemora-
diotherapy or RT alone according to the presence or
absence of other risk factors for recurrence. Patients
should start their adjuvant RT as soon as possible
after surgery (ideally within five weeks (35 days) and
no later than six weeks (42 days)) to avoid reduced
local control and survival due to protracted treatment.
The relevance of traditional risk factors for recurrence
(including extra-capsular spread) and the benefit of
adjuvant chemotherapy with RT in the context of
HPV-positive OPSCC has been questioned by some
studies. However, no change in management of patients
should occur outside clinical trials. Clinical trials which
aim to modify adjuvant treatment based on HPV status
are currently ongoing in the UK and USA.
Ongoing Research
Human papilloma virus status appears to have profound
influence on prognosis and, in the future, potentially on
selection of treatment modality. There are several
ongoing or planned clinical trials for HPV-positive
and HPV-negative OPSCC and recruitment into clinical
trials addressing these issues is highly recommended.
Development of biomarker classifiers for treatment
selection is also high recommended.
Recommendations
• Advanced oropharyngeal carcinoma can be
treated with primary chemoradiotherapy or
transoral surgery and adjuvant
(chemo)radiotherapy (R)
• The N0 neck should be treated electively –
either by radiotherapy or selective neck
dissection (R)
• Patients with advanced nodal (N2 or N3)
disease receiving radical chemoradiotherapy
should have a PET-CT scan 10–12 weeks
after treatment, with a subsequent neck
dissection within 4 weeks if residual abnormal
or equivocal nodal disease is detected (R)
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• Intensity modulated radiotherapy reduces
toxicity in patients treated with radical
radiotherapy, compared with conventional
radiotherapy (R)
• Post-operative chemoradiotherapy is
currently recommended in patients treated
with surgery who have involved primary
tumour resection margins and/or
extracapsular spread of nodal disease.
Otherwise, post-operative radiotherapy alone
may be indicated (R)
Key points
• Oropharyngeal cancer incidence is increasing rapidly
in the UK due to the Human papillomavirus (HPV).
• HPV association confers better outcomes regardless
of treatment modality
• Early stage disease should be receive single modality
treatment
• Advanced disease should receive combined modal-
ity treatment
• PETCT scanning undertaken at 10-12 weeks post
chemo-radiation results in similar survival to
planned neck dissection, but with considerably
fewer patients requiring neck dissection, less mor-
bidity and is cost-effective
• There is insufficient evidence to alter treatment on
the basis of HPV status
• Patients should be offered the opportunity to partici-
pate in the ongoing clinical trials.
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